As reported on PR NewsWire, Orsini has been named a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral treatment recently approved by the US Food and Drug Administration (FDA) for adults with dermatomyositis. The collaboration is intended to support patient access to the therapy and provide specialized pharmacy services for individuals living with the rare autoimmune condition.
Dermatomyositis is an inflammatory autoimmune disease that can cause disabling muscle weakness and painful skin manifestations. In addition to its effects on muscles and skin, the disease may involve multiple organ systems, potentially leading to pulmonary, cardiac, and gastrointestinal complications. Treatment options for affected patients have historically been limited.
LISRAYA is notable as the first FDA-approved targeted therapy specifically indicated for dermatomyositis. The approval marks a significant development in the treatment landscape, offering a new therapeutic approach for a patient population with substantial unmet medical needs.
The drug’s approval was supported by findings from the Phase 3 VALOR trial, described as the largest placebo-controlled study conducted in dermatomyositis to date. Study results demonstrated meaningful improvements across several measures of disease activity among patients receiving brepocitinib. Reported benefits included enhanced overall myositis response, improvements in skin disease and muscle strength, reduced functional disability, and decreased reliance on corticosteroid therapy.
Orsini CEO Brandon Tom highlighted the significance of the approval, noting that the new treatment has the potential to improve outcomes and quality of life for patients affected by dermatomyositis. The company, which specializes in rare disease pharmacy services, will help facilitate access to the therapy and support patients throughout the treatment process.
Priovant executives also emphasized the importance of the partnership, citing Orsini’s experience in rare disease management as a key factor in ensuring efficient patient access. According to Priovant Chief Operating Officer Daniel Herz-Roiphe, the availability of LISRAYA offers renewed optimism for individuals with dermatomyositis, a community that has long faced limited treatment choices.
The partnership underscores growing efforts within the rare disease space to improve access to innovative therapies while providing comprehensive patient support services. As LISRAYA enters clinical practice, healthcare providers and patients will have access to the first targeted treatment specifically approved for dermatomyositis.
